alendronate has been researched along with Muscular Dystrophy, Duchenne in 5 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Muscular Dystrophy, Duchenne: An X-linked recessive muscle disease caused by an inability to synthesize DYSTROPHIN, which is involved with maintaining the integrity of the sarcolemma. Muscle fibers undergo a process that features degeneration and regeneration. Clinical manifestations include proximal weakness in the first few years of life, pseudohypertrophy, cardiomyopathy (see MYOCARDIAL DISEASES), and an increased incidence of impaired mentation. Becker muscular dystrophy is a closely related condition featuring a later onset of disease (usually adolescence) and a slowly progressive course. (Adams et al., Principles of Neurology, 6th ed, p1415)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral alendronate produces an increase in BMD in these patients, with good tolerance and no need for hospitalization, and so improves quality of life and reduces health care costs." | 5.37 | [Alendronate treatment of osteoporosis secondary to Duchenne muscular dystrophy]. ( Ballester Herrera, MJ; Carmona Vilchez, RM; Márquez de La Plata, MA; Medina Cano, E; Palomo Atance, E, 2011) |
| "Osteoporosis is a major problem in patients with Duchenne muscular dystrophy (DMD), due to glucocorticoid therapy and muscle weakness." | 1.56 | Oral bisphosphonate treatment in patients with Duchenne muscular dystrophy on long term glucocorticoid therapy. ( Hornung, L; Khoury, JC; Rutter, MM; Rybalsky, I; Shellenbarger, KC; Tian, C; Wong, BL, 2020) |
| "Oral alendronate produces an increase in BMD in these patients, with good tolerance and no need for hospitalization, and so improves quality of life and reduces health care costs." | 1.37 | [Alendronate treatment of osteoporosis secondary to Duchenne muscular dystrophy]. ( Ballester Herrera, MJ; Carmona Vilchez, RM; Márquez de La Plata, MA; Medina Cano, E; Palomo Atance, E, 2011) |
| "In deflazacort-treated boys, alendronate had a positive effect on BMD z scores; the effect was greatest when given early in the course of disease." | 1.33 | Alendronate in the treatment of low bone mass in steroid-treated boys with Duchennes muscular dystrophy. ( Biggar, WD; Chase, CC; Fielding, LJ; Harris, VA; Hawker, GA; Ridout, R, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tian, C | 1 |
| Wong, BL | 1 |
| Hornung, L | 1 |
| Khoury, JC | 1 |
| Rybalsky, I | 1 |
| Shellenbarger, KC | 1 |
| Rutter, MM | 1 |
| Zheng, WB | 1 |
| Dai, Y | 1 |
| Hu, J | 1 |
| Zhao, DC | 1 |
| Wang, O | 1 |
| Jiang, Y | 1 |
| Xia, WB | 1 |
| Xing, XP | 1 |
| Li, M | 1 |
| Houston, C | 1 |
| Mathews, K | 1 |
| Shibli-Rahhal, A | 1 |
| Palomo Atance, E | 1 |
| Ballester Herrera, MJ | 1 |
| Márquez de La Plata, MA | 1 |
| Medina Cano, E | 1 |
| Carmona Vilchez, RM | 1 |
| Hawker, GA | 1 |
| Ridout, R | 1 |
| Harris, VA | 1 |
| Chase, CC | 1 |
| Fielding, LJ | 1 |
| Biggar, WD | 1 |
5 other studies available for alendronate and Muscular Dystrophy, Duchenne
| Article | Year |
|---|---|
Oral bisphosphonate treatment in patients with Duchenne muscular dystrophy on long term glucocorticoid therapy.
Topics: Absorptiometry, Photon; Adolescent; Alendronate; Bone Density; Bone Density Conservation Agents; Chi | 2020 |
Effects of Bisphosphonates on Osteoporosis Induced by Duchenne Muscular Dystrophy: A Prospective Study.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Child; Diphosphonates; Female; Humans; | 2020 |
Bone density and alendronate effects in Duchenne muscular dystrophy patients.
Topics: Absorptiometry, Photon; Adolescent; Adult; Alendronate; Bone Density; Bone Density Conservation Agen | 2014 |
[Alendronate treatment of osteoporosis secondary to Duchenne muscular dystrophy].
Topics: Alendronate; Bone Density Conservation Agents; Child; Humans; Muscular Dystrophy, Duchenne; Osteopor | 2011 |
Alendronate in the treatment of low bone mass in steroid-treated boys with Duchennes muscular dystrophy.
Topics: Alendronate; Bone and Bones; Bone Density; Child; Glucocorticoids; Humans; Male; Muscular Dystrophy, | 2005 |